Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 1/20 | 0.44 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL547358 | 0.81 | NOTUM (0.50) | HSD17B10KDM4ENOTUMGAAMEN1 | |
| SCHEMBL7689425 | 0.77 | BRPF1 (0.42) | BRPF1PBRM1HSD17B10KDM4ENOTUM | |
| SCHEMBL29951594 | 0.74 | BRPF1 (0.40) | BRPF1PBRM1HSD17B10KDM4ESMN1; SMN2 | |
| SCHEMBL6082830 | 0.73 | TSHR (0.52) | KDM4ESMN1; SMN2CYP1A2CYP3A4NPC1 | |
| SCHEMBL15197090 | 0.72 | PBRM1 (0.45) | BRPF1PBRM1KDM4ENPC1MEN1 | |
| SCHEMBL11201376 | 0.71 | NPSR1 (0.43) | BRPF1 | |
| SCHEMBL15491101 | 0.71 | CSNK2A1 (0.50) | HSD17B10KDM4ENOTUMCYP1A2GAA | |
| SCHEMBL7683073 | 0.70 | SMN1; SMN2 (0.51) | BRPF1PBRM1HSD17B10KDM4ESMN1; SMN2 | |
| SCHEMBL8198680 | 0.69 | GRM1 (0.53) | HSD17B10KDM4ECYP1A2NPC1POLB | |
| SCHEMBL15491102 | 0.67 | POLB (0.39) | BRPF1NOTUMPOLBGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618152-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2468744-A2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20120014914-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-19 | — | — | US | disclosed |
| EP-1441720-B1 | INHIBITORS OF SERINE PROTEASE, PARTICULARLY HEPATITIS C VIRUS NS3-NS4A PROTEASE, INCORPORATING A FUSED RING SYSTEM | VERTEX PHARMA (US) | 2012-01-04 | — | — | EP | disclosed |
| EP-2402009-A1 | Inhibitors of serine protease, particularly hepatitis c virus NS3-NS4A protease, incorporating a fused ring system | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-04 | — | — | EP | disclosed |
| EP-2368900-A2 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2364970-A1 | Processes and intermediates | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-2364984-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-2361925-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-31 | — | — | EP | disclosed |
| EP-2357170-A1 | Processes and intermediates | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-17 | — | — | EP | disclosed |
| CN-1795188-A | Inhibitors of serine proteases, particularly HCV NS 3-NS 4A protease | VERTEX PHARMA (US) | 2006-06-28 | — | — | CN | disclosed |
| EP-1636208-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | Vertex Pharmaceuticals Incorporated (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1613620-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | Vertex Pharmaceuticals Incorporated (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2005077969-A2 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-08-25 | — | — | WO | disclosed |
| WO-2005037860-A2 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCOPORATED (US) | 2005-04-28 | — | — | WO | disclosed |
| US-20050090450-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS, INCORPORATED | 2005-04-28 | — | — | US | disclosed |
| US-20050080017-A1 | Inhibitors of serine proteases, particularly HVC NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED | 2005-04-14 | — | — | US | disclosed |
| WO-2004092161-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004092162-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2003035060-A1 | INHIBITORS OF SERINE PROTEASE, PARTICULARLY HEPATITIS C VIRUS NS3-NS4A PROTEASE, INCORPORATING A FUSED RING SYSTEM | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120014914-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASES | PRSS1, SERPINB1, SPINT2 | BRPF1 4031/4885PBRM1 4096/4885HSD17B10 1534/4885 |
| US-20050090450-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | PRSS1, SERPINB1, SPINT2 | BRPF1 4063/4885PBRM1 4069/4885HSD17B10 1465/4885 |
| US-20050080017-A1 | Inhibitors of serine proteases, particularly HVC NS3-NS4A protease | HPN, PRSS1, SERPINB1 | BRPF1 4105/4885PBRM1 3995/4885HSD17B10 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.